Fed’s Powell opens door to potential rate cuts at Jackson Hole
In recent trading activity, Saira Ramasastry, a director at Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a $2.2 billion market cap company that has delivered an impressive 75% return over the past year, sold shares of the company, according to a filing with the Securities and Exchange Commission. On June 2, Ramasastry sold 5,703 shares at an average price of $46.2023 per share, and on June 3, she sold an additional 2,500 shares at $45.7407 per share. The total value of these transactions amounted to $377,843.
Additionally, on June 3, Ramasastry exercised stock options to acquire 2,500 shares at a price of $14.12 per share, resulting in a transaction valued at $35,300. Following these transactions, Ramasastry no longer holds shares in the company directly.
In other recent news, Mirum Pharmaceuticals reported impressive financial results for the first quarter of 2025, with revenue reaching $111.6 million, surpassing forecasts of $98.02 million. This performance marks a 61% year-over-year increase, driven by strong demand for its commercial medicines and strategic international expansion. The company has raised its full-year revenue guidance to a range of $435-$450 million, reflecting confidence in its ongoing growth trajectory. H.C. Wainwright initiated coverage on Mirum Pharmaceuticals with a Buy rating and a price target of $73, noting the company’s effective commercial strategies and regulatory approvals as growth drivers. JMP Securities and Evercore ISI both raised their price targets for Mirum to $76, maintaining positive outlooks due to the strong sales of Livmarli and raised revenue estimates. Mirum is also advancing its clinical trials, expecting to complete enrollment for the VISTAS trial of volixibat for Primary Sclerosing Cholangitis in the next quarter. These developments underscore Mirum Pharmaceuticals’ potential for sustained growth in the rare disease therapeutics market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.